Saccharomyces cerevisiae fungemia in a head and neck cancer patient: a case report and review of the literature.
We report the case of a 65-year old male who developed Saccharomyces cerevisiae fungemia after completing a course of concomitant chemotherapy and radiation therapy for head and neck carcinoma. He had grade IV oral mucositis, and received Saccharomyces boulardii (Perenterol) orally as treatment for aseptic diarrhoea just before the onset of fungemia. We discuss the epidemiology and pathology of Saccharomyces cerevisiae in the cancer patient population.
Henry
S
S
Department of Oncology and Haematology, Centre Hospitalier Notre-Dame et Reine Fabiola, Grand'Rue 3, 6000 Charleroi Belgium.
D'Hondt
L
L
André
M
M
Holemans
X
X
Canon
J L
JL
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D016469:Fungemia / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009959:Oropharyngeal Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D018570:Risk Assessment; D012441:Saccharomyces cerevisiae / Q000187:drug effects / Q000302:isolation & purification*; D016896:Treatment Outcome; D015002:Yeast, Dried / Q000627:therapeutic use
C009786:perenterol